<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin Y</submitter><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>974-988.e5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11227404</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(7)</volume><pubmed_abstract>Cellular therapies with cardiomyocytes produced from induced pluripotent stem cells (iPSC-CMs) offer a potential route to cardiac regeneration as a treatment for chronic ischemic heart disease. Here, we report successful long-term engraftment and in vivo maturation of autologous iPSC-CMs in two rhesus macaques with small, subclinical chronic myocardial infarctions, all without immunosuppression. Longitudinal positron emission tomography imaging using the sodium/iodide symporter (NIS) reporter gene revealed stable grafts for over 6 and 12 months, with no teratoma formation. Histological analyses suggested capability of the transplanted iPSC-CMs to mature and integrate with endogenous myocardium, with no sign of immune cell infiltration or rejection. By contrast, allogeneic iPSC-CMs were rej</pubmed_abstract><journal>Cell stem cell</journal><pubmed_title>Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques.</pubmed_title><pmcid>PMC11227404</pmcid><funding_grant_id>R01 HL148081</funding_grant_id><funding_grant_id>75N91019D00024</funding_grant_id><funding_grant_id>R01 HL146868</funding_grant_id><pubmed_authors>Zou J</pubmed_authors><pubmed_authors>Schwartzbeck R</pubmed_authors><pubmed_authors>Lin Y</pubmed_authors><pubmed_authors>Taylor JL</pubmed_authors><pubmed_authors>Murry CE</pubmed_authors><pubmed_authors>Jeffries KR</pubmed_authors><pubmed_authors>Boehm M</pubmed_authors><pubmed_authors>Kelly C</pubmed_authors><pubmed_authors>Ferrante EA</pubmed_authors><pubmed_authors>Yu SJ</pubmed_authors><pubmed_authors>Adler SS</pubmed_authors><pubmed_authors>Keeran KJ</pubmed_authors><pubmed_authors>Nakamura K</pubmed_authors><pubmed_authors>Chen MY</pubmed_authors><pubmed_authors>Clevenger RR</pubmed_authors><pubmed_authors>Dunbar CE</pubmed_authors><pubmed_authors>Hunt TJ</pubmed_authors><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Choyke PL</pubmed_authors><pubmed_authors>Neidig LE</pubmed_authors><pubmed_authors>Navarengom K</pubmed_authors><pubmed_authors>Mehta A</pubmed_authors><pubmed_authors>Sato N</pubmed_authors><pubmed_authors>Yu ZX</pubmed_authors><pubmed_authors>Takeda K</pubmed_authors><pubmed_authors>Hong S</pubmed_authors><pubmed_authors>Nakamura DS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-term engraftment and maturation of autologous iPSC-derived cardiomyocytes in two rhesus macaques.</name><description>Cellular therapies with cardiomyocytes produced from induced pluripotent stem cells (iPSC-CMs) offer a potential route to cardiac regeneration as a treatment for chronic ischemic heart disease. Here, we report successful long-term engraftment and in vivo maturation of autologous iPSC-CMs in two rhesus macaques with small, subclinical chronic myocardial infarctions, all without immunosuppression. Longitudinal positron emission tomography imaging using the sodium/iodide symporter (NIS) reporter gene revealed stable grafts for over 6 and 12 months, with no teratoma formation. Histological analyses suggested capability of the transplanted iPSC-CMs to mature and integrate with endogenous myocardium, with no sign of immune cell infiltration or rejection. By contrast, allogeneic iPSC-CMs were rej</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-07-28T03:03:45.009Z</modification><creation>2025-07-28T03:03:45.009Z</creation></dates><accession>S-EPMC11227404</accession><cross_references><pubmed>38843830</pubmed><doi>10.1016/j.stem.2024.05.005</doi></cross_references></HashMap>